Community Screening Study of Diabetic Retinopathy in Tianjin in 2024
NCT ID: NCT06478407
Last Updated: 2024-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
18000 participants
OBSERVATIONAL
2024-03-28
2025-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Diabetic Retinopathy Screening, Prevention and Control Program
NCT04240652
Shanghai Beixinjing Diabetic Eyes Study
NCT03571217
Study of Natural Course Progression of Diabetic Retinopathy
NCT06269419
Shanghai Diabetic Eye Study in Diabetics
NCT03579797
Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
NCT03025399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic retinopathy screening group
Diabetes patients in the community to accept unified eye test, confirm whether patients with diabetic retinopathy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2: diabetes
Exclusion Criteria
2: In the last 6 months, you have not lived in your place of residence
3: Have a serious mental illness
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Eye Hospital
OTHER
Li Xiaorong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Xiaorong
PROFESSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaorong Li, professor
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University Eye Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.